Md. Code Regs. 10.34.29.02

Current through Register Vol. 51, No. 22, November 1, 2024
Section 10.34.29.02 - Content of Protocol
A. A protocol shall:
(1) Be:
(a) Written; and
(b) Condition or disease-state specific; and
(2) Contain the following:
(a) The condition that the protocol is designed to manage;
(b) A list of medications that may be used under the auspices of the protocol;
(c) Monitoring parameters including laboratory tests for the:
(i) Condition; and
(ii) Medication employed;
(d) A list of circumstances requiring contact with the authorized prescriber or authorized prescribers who are a party to the prescriber-pharmacist agreement;
(e) A statement prohibiting substitution of a chemically dissimilar drug product by the pharmacist for the product prescribed by the authorized prescriber unless permitted in the therapy management contract;
(f) A list of circumstances under which the pharmacist may alter doses, modify the treatment regimen, or switch the agent under the terms of the therapy management contract;
(g) Information to be documented;
(h) A listing of provisions within the protocol that may be customized within a therapy management contract; and
(i) An action plan for situations when the pharmacist encounters a situation that is not addressed in the protocol.
B. A protocol may authorize:
(1) The modification, continuation, and discontinuation of drug therapy;
(2) The ordering of laboratory tests;
(3) Other patient care management measures related to monitoring or improving the outcomes of drug or device therapy; and
(4) For protocols by a licensed physician and licensed pharmacist, the initiation of drug therapy under written, disease-state specific protocols.
C. A protocol may not authorize acts that exceed the scope of practice of the parties to the prescriber-pharmacist agreement.
D. Technical modifications to the protocol shall be registered with the Board of Pharmacy within 30 days of the technical modification.

Md. Code Regs. 10.34.29.02

Regulation .02 amended effective 43:6 Md. R. 409, eff.3/28/2016